Is nuclear expression of Y box‐binding protein‐1 a new prognostic factor in ovarian serous adenocarcinoma?

Nuclear expression of Y box‐binding protein (YB‐1), a member of the DNA binding protein family, has been reported to be much more highly concentrated in cisplatin‐resistant cell lines than in their parental counterparts, suggesting an ability to limit cisplatin sensitivity. Moreover, YB‐1 plays a key role in P‐glycoprotein expression. Because ovarian carcinoma traditionally has been treated with cisplatin‐based chemotherapy, the sensitivity of the tumors to chemotherapy could reflect a particular prognosis in patients with ovarian carcinoma. The aim of the current study was to determine whether YB‐1 expression correlated with prognosis in ovarian serous adenocarcinoma patients.

[1]  Y. Iwamoto,et al.  Nuclear expression of YB-1 protein correlates with P-glycoprotein expression in human osteosarcoma. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[2]  K. Kohno,et al.  Direct Involvement of the Y-box Binding Protein YB-1 in Genotoxic Stress-induced Activation of the Human Multidrug Resistance 1 Gene* , 1998, The Journal of Biological Chemistry.

[3]  X. Chen,et al.  [The expression of glutathione S-transferase pi in human ovarian cancer as an indicator of resistance to chemotherapy]. , 1998, Zhonghua fu chan ke za zhi.

[4]  K. Kohno,et al.  Nuclear translocation of the Y‐box binding protein by ultraviolet irradiation , 1997, FEBS letters.

[5]  F. Oesch,et al.  Glutathione, GlutathioneS-Transferase α and π, and Aldehyde Dehydrogenase Content in Relationship to Drug Resistance in Ovarian Cancer , 1997 .

[6]  F. Oesch,et al.  Glutathione, glutathione S-transferase alpha and pi, and aldehyde dehydrogenase content in relationship to drug resistance in ovarian cancer. , 1997, Gynecologic oncology.

[7]  B. Dörken,et al.  Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression , 1997, Nature Medicine.

[8]  M. Tanimoto,et al.  Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. , 1996, Cancer research.

[9]  K. Kohno,et al.  A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. , 1996, Cancer research.

[10]  J. Yodoi,et al.  Cellular levels of thioredoxin associated with drug sensitivity to cisplatin, mitomycin C, doxorubicin, and etoposide. , 1995, Cancer research.

[11]  M. Tsuneyoshi,et al.  Leiomyosarcoma Versus Bizarre and Cellular Leiomyomas of the Uterus: A Comparative Study Based on the MIB‐1 and Proliferating Cell Nuclear Antigen Indices, p53 Expression, DNA Flow Cytometry, and Muscle Specific Actins , 1995, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[12]  K. Kohno,et al.  Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells. , 1994, Cancer research.

[13]  J. Berek,et al.  The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. , 1994, American journal of obstetrics and gynecology.

[14]  H. Furumoto,et al.  Expression of glutathione S‐transferase‐π in human ovarian cancer as an indicator of resistance to chemotherapy , 1994, Gynecologic oncology.

[15]  K. Kohno,et al.  Reduction of drug accumulation in cisplatin-resistant variants of human prostatic cancer PC-3 cell line. , 1993, The Journal of urology.

[16]  T. Ishikawa,et al.  Glutathione-associated cis-diamminedichloroplatinum(II) metabolism and ATP-dependent efflux from leukemia cells. Molecular characterization of glutathione-platinum complex and its biological significance. , 1993, The Journal of biological chemistry.

[17]  K. Kohno,et al.  Enhanced expression of the human multidrug resistance 1 gene in response to UV light irradiation. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[18]  A. Godwin,et al.  High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[19]  N. Saijo,et al.  Metallothionein content correlates with the sensitivity of human small cell lung cancer cell lines to cisplatin. , 1991, Cancer research.

[20]  C. Yan,et al.  Molecular cloning and characterization of interferon alpha/beta response element binding factors of the murine (2'-5')oligoadenylate synthetase ME-12 gene. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[21]  S. Kato,et al.  Tissue-specific enhancer of the human multidrug-resistance (MDR1) gene. , 1990, The Journal of biological chemistry.

[22]  A. Fojo,et al.  Increased DNA repair as a mechanism of acquired resistance to cis-diamminedichloroplatinum (II) in human ovarian cancer cell lines. , 1988, Cancer research.

[23]  D. K. Didier,et al.  Characterization of the cDNA encoding a protein binding to the major histocompatibility complex class II Y box. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[24]  A. Eastman,et al.  Enhanced DNA repair as a mechanism of resistance to cis-diamminedichloroplatinum(II). , 1988, Biochemistry.

[25]  S. Howell,et al.  cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells. , 1988, Cancer research.

[26]  E. Wiltshaw,et al.  Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary. , 1976, Cancer treatment reports.